BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

Mapping Intimacies ◽

10.47660/cbr.2020.16625 ◽

2021 ◽

Author(s):

Mittermayer Barreto Santiago ◽

Richard Furie ◽

Brad Rovin ◽

Frédéric Houssiau ◽

Zahir Amoura ◽

...

Keyword(s):

Lupus Nephritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

Arthritis & Rheumatology ◽

10.1002/art.39722 ◽

2016 ◽

Vol 68 (9) ◽

pp. 2174-2183 ◽

Cited By ~ 55

Author(s):

Brad H. Rovin ◽

Ronald F. van Vollenhoven ◽

Cynthia Aranow ◽

Carrie Wagner ◽

Robert Gordon ◽

...

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

OP0047 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.3974 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 78.2-78 ◽

Cited By ~ 7

Author(s):

R. van Vollenhoven ◽

C. Aranow ◽

B. Rovin ◽

C. Wagner ◽

B. Zhou ◽

...

Keyword(s):

Lupus Nephritis ◽

Phase 2 ◽

Proof Of Concept ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Concept Study ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

Faculty Opinions recommendation of A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726310595.793547380 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

Faculty Opinions recommendation of A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726310595.793533038 ◽

2017 ◽

Author(s):

Tak Mao Chan ◽

Susan Yung

Keyword(s):

Lupus Nephritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Active Lupus Nephritis ◽

Active Lupus

Download Full-text

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis

Kidney International ◽

10.1016/j.kint.2018.08.025 ◽

2019 ◽

Vol 95 (1) ◽

pp. 219-231 ◽

Cited By ~ 49

Author(s):

Brad H. Rovin ◽

Neil Solomons ◽

William F. Pendergraft ◽

Mary Anne Dooley ◽

James Tumlin ◽

...

Keyword(s):

Lupus Nephritis ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized Controlled ◽

Active Lupus Nephritis ◽

Dose Ranging ◽

Active Lupus

Download Full-text

Faculty Opinions recommendation of A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734432447.793577107 ◽

2020 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Lupus Nephritis ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized Controlled ◽

Active Lupus Nephritis ◽

Dose Ranging ◽

Active Lupus

Download Full-text

Faculty Opinions recommendation of A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734432447.793576804 ◽

2020 ◽

Author(s):

Tak Mao Chan ◽

Susan Yung

Keyword(s):

Lupus Nephritis ◽

Blind Study ◽

Double Blind Study ◽

Efficacy And Safety ◽

Double Blind ◽

Randomized Controlled ◽

Active Lupus Nephritis ◽

Dose Ranging ◽

Active Lupus

Download Full-text

IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

10.1055/s-0038-1676032 ◽

2018 ◽

Author(s):

Tilman Polster ◽

Lieven Lagae ◽

Joseph Sullivan ◽

Ulrich Brandl ◽

Arne Herting ◽

...

Keyword(s):

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

First Results

Download Full-text

Analysis of adverse events in adult patients with acromegaly receiving oral octreotide capsules: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep613 ◽

2020 ◽

Author(s):

Artak Labadzhyan ◽

Susan Samson ◽

Lisa Nachtigall ◽

Maria Fleseriu ◽

Mark E Molitch ◽

...

Keyword(s):

Adverse Events ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep668 ◽

2020 ◽

Author(s):

Lisa Nachtigall ◽

Susan Samson ◽

Maria Fleseriu ◽

Marek Bolanowski ◽

Molitch Mark E ◽

...

Keyword(s):

Somatostatin Receptor ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Receptor Ligand ◽

Double Blind Placebo ◽

Long Acting ◽

Somatostatin Receptor Ligand

Download Full-text